789 related articles for article (PubMed ID: 16848811)
1. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
[TBL] [Abstract][Full Text] [Related]
2. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
3. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
4. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
5. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
6. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
8. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
[TBL] [Abstract][Full Text] [Related]
9. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
10. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
13. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
15. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
16. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
19. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
Nomura F; Ishijima M; Kuwa K; Tanaka N; Nakai T; Ohnishi K
Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
[TBL] [Abstract][Full Text] [Related]
20. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
Lamerz R; Runge M; Stieber P; Meissner E
Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
